Jennifer L Whitwell1, J Eric Ahlskog2, Nirubol Tosakulwong3, Matthew L Senjem4, Anthony J Spychalla5, Ronald C Petersen2, Clifford R Jack5, Val J Lowe5, Keith A Josephs2. 1. Department of Radiology, Mayo Clinic, Rochester, MN, United States. Electronic address: Whitwell.jennifer@mayo.edu. 2. Department of Neurology, Mayo Clinic, Rochester, MN, United States. 3. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States. 4. Department of Radiology, Mayo Clinic, Rochester, MN, United States; Department of Information Technology, Mayo Clinic, Rochester, MN, United States. 5. Department of Radiology, Mayo Clinic, Rochester, MN, United States.
Abstract
INTRODUCTION: Little is known about Alzheimer's disease molecular proteins, beta-amyloid and paired helical filament (PHF) tau, in progressive supranuclear palsy (PSP). Recent techniques have been developed to allow for investigations of these proteins in PSP. We determined the frequency of beta-amyloid deposition in PSP, and whether beta-amyloid deposition in PSP is associated with PHF-tau deposition pattern, or clinical features. METHODS: Thirty probable PSP participants underwent MRI, [18F]AV-1451 PET and Pittsburgh compound B (PiB) PET. Apolipoprotein (APOE) genotyping was also performed. A global PiB standard-uptake value ratio (SUVR) was calculated. AV-1451 SUVRs were calculated for a set of Alzheimer's disease (AD)-related regions and a set of PSP-related regions. Voxel-level analyses were conducted to assess for differences in AV-1451 uptake patterns and MRI atrophy between PiB(+) and PiB(-) cases compared to 60 normal PiB(-) controls. Statistical testing for correlations and associations between variables of interest were also performed. RESULTS: Twelve subjects (40%) showed beta-amyloid deposition. Higher PiB SUVR correlated with older age but not with AV-1451 SUVR in the AD- or PSP-related regions. Higher AV-1451 SUVR in AD-related regions was associated with higher AV-1451 SUVR in PSP-related regions. We found little evidence for beta-amyloid related differences in clinical metrics, proportion of APOE e4 carriers, pattern of AV-1451 uptake, or pattern of atrophy. CONCLUSION: Beta-amyloid deposition occurs in a relatively high proportion of PSP subjects. Unlike in Alzheimer's disease, however, there is little evidence that beta-amyloid, and PHF-tau, play a significant role in neurodegeneration in PSP.
INTRODUCTION: Little is known about Alzheimer's disease molecular proteins, beta-amyloid and paired helical filament (PHF) tau, in progressive supranuclear palsy (PSP). Recent techniques have been developed to allow for investigations of these proteins in PSP. We determined the frequency of beta-amyloid deposition in PSP, and whether beta-amyloid deposition in PSP is associated with PHF-tau deposition pattern, or clinical features. METHODS: Thirty probable PSPparticipants underwent MRI, [18F]AV-1451 PET and Pittsburgh compound B (PiB) PET. Apolipoprotein (APOE) genotyping was also performed. A global PiB standard-uptake value ratio (SUVR) was calculated. AV-1451 SUVRs were calculated for a set of Alzheimer's disease (AD)-related regions and a set of PSP-related regions. Voxel-level analyses were conducted to assess for differences in AV-1451 uptake patterns and MRI atrophy between PiB(+) and PiB(-) cases compared to 60 normal PiB(-) controls. Statistical testing for correlations and associations between variables of interest were also performed. RESULTS: Twelve subjects (40%) showed beta-amyloid deposition. Higher PiB SUVR correlated with older age but not with AV-1451 SUVR in the AD- or PSP-related regions. Higher AV-1451 SUVR in AD-related regions was associated with higher AV-1451 SUVR in PSP-related regions. We found little evidence for beta-amyloid related differences in clinical metrics, proportion of APOE e4 carriers, pattern of AV-1451 uptake, or pattern of atrophy. CONCLUSION: Beta-amyloid deposition occurs in a relatively high proportion of PSP subjects. Unlike in Alzheimer's disease, however, there is little evidence that beta-amyloid, and PHF-tau, play a significant role in neurodegeneration in PSP.
Authors: David T Chien; Shadfar Bahri; A Katrin Szardenings; Joseph C Walsh; Fanrong Mu; Min-Ying Su; William R Shankle; Arkadij Elizarov; Hartmuth C Kolb Journal: J Alzheimers Dis Date: 2013 Impact factor: 4.472
Authors: Chun-Fang Xia; Janna Arteaga; Gang Chen; Umesh Gangadharmath; Luis F Gomez; Dhanalakshmi Kasi; Chung Lam; Qianwa Liang; Changhui Liu; Vani P Mocharla; Fanrong Mu; Anjana Sinha; Helen Su; A Katrin Szardenings; Joseph C Walsh; Eric Wang; Chul Yu; Wei Zhang; Tieming Zhao; Hartmuth C Kolb Journal: Alzheimers Dement Date: 2013-02-12 Impact factor: 21.566
Authors: Michelle M Mielke; Heather J Wiste; Stephen D Weigand; David S Knopman; Val J Lowe; Rosebud O Roberts; Yonas E Geda; Dana M Swenson-Dravis; Bradley F Boeve; Matthew L Senjem; Prashanthi Vemuri; Ronald C Petersen; Clifford R Jack Journal: Neurology Date: 2012-09-12 Impact factor: 9.910
Authors: M Baker; I Litvan; H Houlden; J Adamson; D Dickson; J Perez-Tur; J Hardy; T Lynch; E Bigio; M Hutton Journal: Hum Mol Genet Date: 1999-04 Impact factor: 6.150
Authors: Daniel R Schonhaut; Corey T McMillan; Salvatore Spina; Bradford C Dickerson; Andrew Siderowf; Michael D Devous; Richard Tsai; Joseph Winer; David S Russell; Irene Litvan; Erik D Roberson; William W Seeley; Lea T Grinberg; Joel H Kramer; Bruce L Miller; Peter Pressman; Ilya Nasrallah; Suzanne L Baker; Stephen N Gomperts; Keith A Johnson; Murray Grossman; William J Jagust; Adam L Boxer; Gil D Rabinovici Journal: Ann Neurol Date: 2017-10 Impact factor: 10.422
Authors: Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling Journal: Ann Neurol Date: 2015-12-15 Impact factor: 10.422
Authors: Jennifer L Whitwell; Günter U Höglinger; Angelo Antonini; Yvette Bordelon; Adam L Boxer; Carlo Colosimo; Thilo van Eimeren; Lawrence I Golbe; Jan Kassubek; Carolin Kurz; Irene Litvan; Alexander Pantelyat; Gil Rabinovici; Gesine Respondek; Axel Rominger; James B Rowe; Maria Stamelou; Keith A Josephs Journal: Mov Disord Date: 2017-05-13 Impact factor: 10.338
Authors: Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan Journal: Mov Disord Date: 2017-05-03 Impact factor: 10.338
Authors: Kerstin Sander; Tammaryn Lashley; Priya Gami; Thibault Gendron; Mark F Lythgoe; Jonathan D Rohrer; Jonathan M Schott; Tamas Revesz; Nick C Fox; Erik Årstad Journal: Alzheimers Dement Date: 2016-02-15 Impact factor: 21.566
Authors: Jennifer L Whitwell; Nirubol Tosakulwong; Christopher G Schwarz; Hugo Botha; Matthew L Senjem; Anthony J Spychalla; J Eric Ahlskog; David S Knopman; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs Journal: Mov Disord Date: 2018-11-23 Impact factor: 10.338
Authors: Jennifer L Whitwell; Nirubol Tosakulwong; Stephen D Weigand; Jonathan Graff-Radford; Joseph R Duffy; Heather M Clark; Mary M Machulda; Hugo Botha; Rene L Utianski; Christopher G Schwarz; Matthew L Senjem; Edythe A Strand; Nilufer Ertekin-Taner; Clifford R Jack; Val J Lowe; Keith A Josephs Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Rik Ossenkoppele; Gil D Rabinovici; Ruben Smith; Hanna Cho; Michael Schöll; Olof Strandberg; Sebastian Palmqvist; Niklas Mattsson; Shorena Janelidze; Alexander Santillo; Tomas Ohlsson; Jonas Jögi; Richard Tsai; Renaud La Joie; Joel Kramer; Adam L Boxer; Maria L Gorno-Tempini; Bruce L Miller; Jae Y Choi; Young H Ryu; Chul H Lyoo; Oskar Hansson Journal: JAMA Date: 2018-09-18 Impact factor: 56.272
Authors: Irene Sintini; Christopher G Schwarz; Matthew L Senjem; Robert I Reid; Hugo Botha; Farwa Ali; J Eric Ahlskog; Clifford R Jack; Val J Lowe; Keith A Josephs; Jennifer L Whitwell Journal: Parkinsonism Relat Disord Date: 2019-07-02 Impact factor: 4.891
Authors: Keith A Josephs; Nirubol Tosakulwong; Stephen D Weigand; Marina Buciuc; Val J Lowe; Dennis W Dickson; Jennifer L Whitwell Journal: J Nucl Med Date: 2021-09-23 Impact factor: 11.082
Authors: Alma Ghirelli; Nirubol Tosakulwong; Stephen D Weigand; Heather M Clark; Farwa Ali; Hugo Botha; Joseph R Duffy; Rene L Utianski; Marina Buciuc; Melissa E Murray; Sydney A Labuzan; Anthony J Spychalla; Nha Trang Thu Pham; Christopher G Schwarz; Matthew L Senjem; Mary M Machulda; Matthew Baker; Rosa Rademakers; Massimo Filippi; Clifford R Jack; Val J Lowe; Joseph E Parisi; Dennis W Dickson; Keith A Josephs; Jennifer L Whitwell Journal: Ann Neurol Date: 2020-09-12 Impact factor: 10.422
Authors: Rene L Utianski; Peter R Martin; Hugo Botha; Christopher G Schwarz; Joseph R Duffy; Ronald C Petersen; David S Knopman; Heather M Clark; Alissa M Butts; Mary M Machulda; Clifford R Jack; Val J Lowe; Jennifer L Whitwell; Keith A Josephs Journal: Cortex Date: 2019-11-19 Impact factor: 4.027
Authors: Maria Stamelou; Gesine Respondek; Nikolaos Giagkou; Jennifer L Whitwell; Gabor G Kovacs; Günter U Höglinger Journal: Nat Rev Neurol Date: 2021-08-23 Impact factor: 42.937